Please login to the form below

Not currently logged in
Email:
Password:

Ophthotech

This page shows the latest Ophthotech news and features for those working in and with pharma, biotech and healthcare.

Novartis' AMD drug pegpleranib fails phase III programme

Novartis' AMD drug pegpleranib fails phase III programme

The results of two phase III trials of pegpleranib - an anti-PDGF aptamer originally developed by OphthoTech - showed that adding it to therapy with Lucentis (ranibizumab) in patients with the neovascular ... While a minor blow to Novartis as well as

Latest news

  • Novartis licenses Ophthotech eye drug in $1bn deal Novartis licenses Ophthotech eye drug in $1bn deal

    Novartis licenses Ophthotech eye drug in $1bn deal. Fovista is a potential first-in-class treatment for wet AMD. ... Ophthotech has retained rights to the drug in the US and will also earn royalties on overseas sales.

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    1, 400. Ophthotech / Novartis. Commercialisation. 1. and co-development licence. Fovista (start p3) for treatment of wet age-related macular degeneration.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics